Form 4: Axogen Director Amy McBride Wendell Sells 5,000 Shares Under 10b5-1 Plan

Director Amy McBride Wendell sold 5,000 shares of Axogen, Inc. common stock on March 3, 2025, at a weighted average price of $20.02 per share, according to a Form 4 filing with the SEC.

Summary

• On March 3, 2025, Amy McBride Wendell, a director of Axogen, Inc., sold 5,000 shares of common stock.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan.
• The shares were sold at a weighted average price of $20.02, with individual transactions ranging from $19.91 to $20.15 per share.
• Following the transaction, Wendell directly owns 97,899 shares of Axogen common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports a sale of shares under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Sales by company insiders are routinely monitored by investors. Sales under a 10b5-1 plan are generally viewed as less impactful than discretionary sales, as they are pre-arranged.

Stakeholder Impact

• The sale of shares by a director could have a minor negative impact on shareholder sentiment, although the use of a 10b5-1 plan mitigates this concern.

Key Dates